晖致 VTRS

Mr. Scott A. Smith, Chief Executive Officer (since April 2023), Viatris. President (2018-2023), BioAtla, Inc. (NASDAQ: BCAB) (BioAtla), a global biotechnology company focused on the development of Conditionally Active Biologics antibody therapeutics. Served as an executive (2008-2018), rising up the ranks from SVP and Global Head of Immunology to President of Inflammation and Immunology and then, beginning in 2017, President and Chief Operating Officer, Celgene Corporation, a global biopharmaceutical company. Other Current Public Company Boards: BioAtla (since 2020), Director. Former Public Company Boards: Apexigen, Inc. (2019-2023 when it was acquired by Pyxis Oncology, Inc.), Director and most recently member of the Compensation and Corporate Governance and Nominating Committees. Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (2017-2020), Director and Chair of the Compensation and Nominating and Governance Committees. Former Private Company Boards: Triumvira Immunologics, Inc. (2018-2023), Director and Chairman. Refuge Biotechnologies, Inc. (2018-2022), Director. F-star Therapeutics, Inc. (2018-2020), (2018-2020), Chairman and member of the Audit and Nominating and Corporate Governance Committees.

Dr. Le Goff has served as Chief Commercial Officer since April 15, 2024. Her responsibilities include oversight of the Company's global commercial organization, including the Developed Markets, Emerging Markets, JANZ and Greater China segments, and the Company's Global Commercial functions, including Global Strategic Marketing, Global Market Access and Value, Global Commercial Insights & Analytics, and Global Commercial Development. Prior to joining the Company, Dr. Le Goff held roles at biotechnology companies, most recently as President, Chief Executive Officer, and Director of Imunon, Inc. (Imunon), a clinical stage biotechnology company, from July 2022 until March 2024, where she led an organizational turnaround and rebranding effort (Imunon was known as Celsion Corporation until September 2022). Prior to Imunon, she was Chief Commercial Officer of Moderna, Inc. from January 2021 through January 2022 and served in various roles at Amgen Inc. from June 2015 to January 2021, including President of the U.S. business from March 2019 to January 2021, Senior Vice President of Global Product Strategy and Commercial Innovation from June 2018 to March 2019 and President of the Europe Region from June 2015 to May 2018. Dr. Le Goff also held various positions within the Roche Group, a publicly traded Swiss multinational healthcare company, including President of Roche's French affiliate from May 2012 to May 2015 and Senior Vice President Global Neuroscience and Rare Diseases Business Unit from 2011 to May 2012. Dr. Le Goff served on the board of directors of Longboard Pharmaceuticals Inc., a clinical-stage biopharmaceutical company from March 2021 until December 2024 when the company was acquired by H. Lundbeck A/S, most recently serving on that company's Audit and Nominating and Corporate Governance Committees, and previously served on the boards of directors of EuroAPI S.A., which develops, manufactures, markets and distributes APIs and intermediates used in the formulation of medicines for human and veterinary use, from April 2022 to January 2023, Acticor Biotech SAS, a clinical stage biopharmaceutical company, from May 2022 to December 2023, and CFAO Group, a trading company, from October 2014 to October 2020.

Mr. Enrietti has served as Viatris' Chief Administrative and Transformation Officer since August 15, 2025. His responsibilities include oversight of the Company's Human Relations, Corporate Affairs, IT, Information Security, Business Transformation, and Corporate Services. Mr. Enrietti most recently served as Viatris' Chief People Officer where he led the strategy and execution of HR, global workplaces and real estate. Prior to the Combination, he served as Mylan's Head of Global Total Rewards & HR M&A, with responsibilities that included the design, development and implementation of the company's global executive and broad-based compensation and equity programs, employee benefit programs and oversight of benefit activities related to corporate M&A and divestitures.

Ms. Melina E. Higgins, Held senior roles of increasing responsibility including Partner (2002-2010) and Managing Director (2001-2010) and served as a member of the Investment Committee of the Principal Investment Area, Head of the Americas for Private Debt and co-Chairperson of the Investment Advisory Committee for GS Mezzanine Partners funds, The Goldman Sachs Group, Inc. (NYSE: GS). Other Current Public Company Boards: Genworth Financial Inc. (NYSE: GNW) (since 2013), non-executive Chair (since 2021) and member of the Audit and Management Development & Compensation Committees. Current Private Company Boards: Director and non-executive chair of the Board (since 2016), Antares Capital Management LLC., a private limited liability company that provides financing solutions for middle market, private equity-backed transactions. Former Public Company Boards: Mylan (2013-the closing of the Combination in 2020), Director, most recently Chair of the Finance Committee, and member of the Audit, Compensation, and Executive Committees. NextGen Acquisition Corp II (March 2021 until its merger with Virgin Orbit in December 2021) (a special purpose acquisition company), Director, Chair of the Nominating and Corporate Governance Committee and member of the Audit and Compensation Committees. Other Organizations: Member, Women's Leadership Board of Harvard University's John F. Kennedy School of Government.

Mr. Mark W. Parrish, Senior Advisor, Frazier Healthcare Ventures, a healthcare-oriented growth equity firm. Executive Vice Chairman (2018-2019), Chief Executive Officer (2008-2018), Executive Chairman (2008-2013), TridentUSA Health Services, a provider of mobile X-ray and laboratory services to the long-term care industry. In February 2019, TridentUSA filed for protection under Chapter 11 of the U.S. Bankruptcy Code and emerged from bankruptcy in September 2019 Held management roles of increasing responsibility (1993-2007) including Chief Executive Officer, Healthcare Supply Chain Services (2006-2007), Cardinal Health Inc. and its affiliates. Other Current Public Company Boards: Omnicell, Inc. (NASDAQ: OMCL) (since 2013), Director, and member of the Audit and Compensation Committees. Current Private Company Boards: Safecor Health, LLC (since 2022), a private limited liability company that provides unit dose drug packaging services to hospitals and long-term care facilities, non-executive Chair. Former Public Company Boards: Mylan: (2009-the closing of the Combination in 2020), most recently Lead Independent Director and Vice Chairman, Chair of the Compliance Committee and member of the Audit, Executive, Governance and Nominating, and Risk Oversight Committees. Former Private Company Boards: Comprehensive Pharmacy Services (2019-2023), a private company that specializes in the outsourcing of hospital pharmacies, Director. Golden State Medical Supply (2014-2019 when it was acquired by Court Square), a private company that specializes in meeting unique labeling and sizing needs and pharmaceutical packaging, serialization, and distribution, Director. Silvergate Pharmaceuticals (2013-2019), a private company that develops and commercializes pediatric medications, Director. Other Organizations: President and Chief Executive Officer (2008-2025), International Federation of Pharmaceutical Wholesalers, an association of pharmaceutical wholesalers and pharmaceutical supply chain service companies.

Ms. JoEllen Lyons Dillon, Executive Vice President, Strategic Developments and Capital Markets (2014-2017); Chief Legal Officer and Corporate Secretary, The ExOne Company (2013-2017). ExOne merged with Desktop Metal (NYSE: DM) in November 2021. ExOne was a global provider of three-dimensional (3D) printing machines and printed products, materials and other services to industrial customers creating products in metal on a worldwide basis. Partner (2002-2011), Reed Smith LLP, a law firm. Partner (1997-2002), Buchanan Ingersoll & Rooney PC, a law firm (joined the firm in 1988). Ms. Dillon also brings CS Experience obtained through her legal and regulatory background, in addition to ongoing education programs Completed certification Board Governance: Navigating Emerging Technologies and More in a Complex World at Cornell University in November 2023. Former Public Company Boards: World Wrestling Entertainment, Inc. (2022-2023) (now known as World Wrestling, LLC), Director. Mylan (2014-the closing of the Combination in 2020), Director, most recently Chair of the Compensation and Governance and Nominating Committees and member of the Audit, Compliance and Executive Committees. Other Organizations: Trustee, S. K. Rockwell Conservation Fund, a non-profit corporation established with the principal concept to preserve and enhance environmental resources.

Mr. Richard A. Mark, C.P.A., Partner (2002-2015), Deloitte & Touche LLP (Deloitte). Audit Partner (1988-2002), Audit Manager (1981-1988), Senior Auditor (1977-1981), Arthur Andersen & Co. Other Current Public Company Boards: Six funds/business development companies in the Goldman Sachs Fund Complex (Goldman Sachs BDC, Inc. (GSBDC) (NYSE: GSBD) (since 2020), Director, Chair of the Audit Committee and member of the Compliance, Governance and Nominating, and Contract Review Committees; Goldman Sachs Private Credit Corp. (since 2022), Director, Chair of the Audit Committee and member of the Compliance, Governance and Nominating, and Contract Review Committees, Goldman Sachs Private Middle Market Credit II LLC (since 2025), Director, Chair of the Audit Committee and member of the Governance and Nominating Committee, Compliance Committee, and Contract Review Committee, West Bay BDC LLC (since 2025), Director, Chair of the Audit Committee, and member of the Governance and Nominating Committee, Compliance Committee, and Contract Review Committee, Phillip Street Middle Market Lending Fund LLC (since 2026), Director and Audit Committee Chair, and Silver Capital Holdings LLC (since 2026), Director and Audit Committee Chair). Former Public Company Boards: Mylan (2019-the closing of the Combination in 2020), Director and most recently member of the Audit and Finance Committees. Funds/Business Development Companies in the Goldman Sachs Fund Complex (Goldman Sachs Middle Market Lending Corp. (2016-2020 when it merged with GSBDC), Director, most recently Chair of the Audit Committee and member of Compliance, Governance and Nominating, and Contract Review Committees and Goldman Sachs Middle Market Lending Corp. II (2020 - 2025 when it merged with Goldman Sachs Private Credit Corp), Director, Chair of the Audit Committee and member of the Compliance, Governance and Nominating, and Contract Review Committees). Katy Industries, Inc. (2015-2016), Chairman and most recently member of the Audit Committee. Former Private Company Boards: Northwestern Memorial Healthcare (2014-2015), Director and member of the Executive and Nominating and Governance Committees. Cadence Health (1993-2014 when it merged with Northwestern), Director. Other Organizations: Director and Chair of the Finance Committee, Home Centered Care Institute, a not-for-profit corporation, which promotes access to home-based primary care for medically complex patients who are either homebound or home-limited. Former Director, Almost Home Kids, a not-for-profit corporation affiliated with Lurie Children's Hospital of Chicago, a provider of transitional care to children with complicated health needs, training for their families, and respite care.

Mr. Leo Groothuis, General Counsel (2022-present), HAL Investments, the Dutch investment subsidiary of HAL Holding N.V., a public international investment company listed on the Amsterdam stock exchange, which is focused on increasing shareholder value. Partner (2006-2022), NautaDutilh, a law firm (joined the firm in October 1996). Key Skills and Experience: Corporate Governance, Global Business, Legal and Regulatory Oversight, Risk Oversight/Compliance, and Strategy and M&A Experience acquired during his legal career at NautaDutilh, where he had been a trusted C-suite and board advisor to some of the largest companies in both Europe and the U.S., which resulted in him being recognized as a top lawyer and thought leader in corporate governance, capital markets, and M&A for the guidance he had provided to numerous multi-national private and public companies on significant complex strategic transactions. Mr. Groothuis also brings CS Experience obtained through his active involvement in the development and execution of HAL Investments' CS strategies. Current Private Company Boards: Non-executive Director (since 2025), Koppert Group B.V., a private company that provides natural solutions to cultivate healthier and safer agricultural crops. Other Organizations: Director, Stichting Continuiteit IHC and B.V. Finance Continuiteit IHC, Dutch entities that together are the sole shareholders of Royal IHC, a private international shipbuilding company.

Ms. Elisha W. Finney, Executive Vice President (2012-2017), Chief Financial Officer (April 1999-May 2017), Senior Vice President (2005-2012), Vice President of Finance (1999-2005), joined the company in 1988, Varian Medical Systems, Inc. Other Current Public Company Boards: Mettler-Toledo International Inc. (NYSE: MTD) (since 2017), Director and Chair of the Audit Committee. ICU Medical, Inc. (NASDAQ: ICUI) (since 2016), Director, Chair of the Nominating and Governance Committee, and member of the Audit and Compliance Committees. Former Public Company Boards: NanoString Technologies, Inc (2017-2024), Director and Chair of the Audit Committee. iRobot Corporation (NASDAQ: IRBT) (2017-2021), Director and member of the Audit and Compensation and Talent Committees. Cutera, Inc. (NASDAQ: CUTR) (2017-2019), Director, Chair of the Audit Committee, and member of the Enterprise Risk Committee. Altera Corporation (2011-2015 when acquired by Intel Corporation), Director and Chair of the Audit Committee. Thoratec Corporation (2007-2013), Director and Chair of the Audit Committee.

Mr. Wyllie Don Cornwell, Vice Chair (2009), Founder, Chairman and Chief Executive Officer (1988-2009), Granite Broadcasting Corporation. Chief Operating Officer (COO), Corporate Finance Department (1980-1988), Vice President, Investment Banking (1976-1988); joined the company in 1971, Goldman, Sachs & Co. Former Public Company Boards: American International Group, Inc. (NYSE: AIG) (2011-2024), Director and most recently member of the Audit and Nominating and Corporate Governance Committees. Natura & Co Holding S.A. (NYSE: NTCO) (2020-2023), Director and most recently member of the Corporate Governance Committee. Avon Products, Inc. (2002-2020 when acquired by Natura), Director. Pfizer (NYSE: PFE) (1997- the closing of the combination of Mylan N.V. (Mylan) with Pfizer's Upjohn business (the Upjohn business) through a Reverse Morris Trust transaction (the Combination) in 2020), Director, and most recently Chair of the Regulatory and Compliance Committee and member of the Governance and Sustainability Committee; also, previously Chair of the Audit Committee. Other Organizations: Vice Chairman and Lead Director of the Board of Directors, Blue Meridian Partners, a partnership of philanthropists that invests in strategies to impact social problems confronting young people and families in poverty Board of Trustees, Occidental College, and Vice Chair of the Investment Committee Advisory, Orca Biosystems, Inc., a private biotechnology company developing high-precision cell therapies for the treatment of cancer and autoimmune diseases.

On August 4, 2025, the Board of Directors of Viatris Inc. appointed David Simmons as an independent member of the Board, effective immediately. Chief Executive Officer (since 2023), Caliber Holdings Corporation, a private multi-site operator of auto body collision repair centers (Caliber). Senior Advisor (since 2012), Abingworth LLP, a life sciences venture capital firm. Operating Partner (2022-2023), Hellman & Friedman, LLC, a private equity firm. Chairman and Chief Executive Officer (2012-2022) PPD, Inc., a global contract pharmaceutical research organization acquired by Themo Fisher Scientific Inc. in 2021. President and General Manager, Emerging Markets and Established Products (2010-2012), management roles of increasing responsibility (1996-2010), including President and General Manager, Established Products, President, Pharmaceuticals Eastern Europe, Vice President, Marketing Canada, President, Pharmaceuticals Greece, Cyprus and Malta Affiliates, Pfizer. Human Capital Management gained as the Chief Executive Officer of Caliber. Other Current Private Company Boards: Cordis (since 2022), Director. Former Private Company Boards: Launch Therapeutics, Inc. (2022 - 2025), Chairman; Curia Global, Inc. (2018 - 2020), Director; Medline Industries, Inc. (2022 - 2024), Director. Former Public Company Boards: PPD (2012 - 2022 following its acquisition by Thermo Fisher Scientific, Inc.), Chairman; Owens & Minor, Inc. (NYSE: OMI) (2013 - 2018), Director. Other Organizations: Trustee, David and Melissa Simmons Family Foundation; Trustee, The Linsly School.

On May 4, 2026, the Board of Directors of the Company appointed Paul Campbell, Viatris' current Chief Accounting Officer and Corporate Controller, to also serve as interim Chief Financial Officer of the Company, effective May 8, 2026. Mr. Campbell, age 59, has served as Viatris' Chief Accounting Officer and Corporate Controller since the closing of the combination of Mylan N.V. (Mylan) with Pfizer's Upjohn business (the Combination) on November 16, 2020. As Chief Accounting Officer and Corporate Controller, he is responsible for oversight of the day-to-day operations of the accounting and finance functions of the Company, including planning, implementing, and managing the Company's finance and accounting activities. Prior to the closing of the Combination, Mr. Campbell served as Mylan's Chief Accounting Officer, Senior Vice President and Controller. Before his appointment as Chief Accounting Officer in November 2015, Mr. Campbell served as Mylan's Senior Vice President and Controller beginning in May 2015, with responsibility for overseeing the company's accounting and financial operations and reporting, and he previously held roles of increasing responsibility at Mylan since 2002.

Mr. Maletta has served as Viatris' Chief Legal Officer since February 9, 2026. His responsibilities include oversight of the Company's global legal organization, including securities, global contracts, labor and employment, global regulatory, business development, litigation, and intellectual property, and, together with the Compliance and Risk Oversight Committee, overseeing the Company's compliance function, among other areas. Prior to joining the Company, Mr. Maletta served as Par Health Inc.'s (a company spun-off from Mallinckrodt plc following its merger with Endo, Inc.) Chief Legal Officer and Corporate Secretary from August 2025 to January 2026 where he had global responsibility for all legal matters and led that company's government affairs function. From May 2015 to August 2025, Mr. Maletta served as Executive Vice President and Chief Legal Officer of Endo International plc and its successor Endo, Inc., (collectively, Endo) and concurrently served as Corporate Secretary for Endo from June 2020 to August 2025. From 2002 to 2015, Mr. Maletta worked for Allergan Inc., rising to Vice President, Associate General Counsel and Corporate Secretary. In that role, he provided legal support for major transactions, public company compliance, and corporate governance, while also supporting business units and corporate functions.

On February 3, 2026, the Company also announced that Matthew Maletta will join the Company as Chief Legal Officer on February 9, 2026. Mr. Maletta is a seasoned legal professional in the pharmaceutical industry, having served from 2015 to 2025 as Executive Vice President, Chief Legal Officer and Secretary of Endo, Inc. Maletta is an accomplished public company executive, with nearly 30 years of legal experience and deep expertise in leading legal teams for both generic and branded pharmaceutical companies. From 2015 to 2025, he served as Executive Vice President, Chief Legal Officer and Corporate Secretary at Endo, where he oversaw Endo's merger with Mallinckrodt and the subsequent spin-off of Par Health. Prior to that, he served for over a decade in the legal department at Allergan, rising to Vice President, Associate General Counsel and Corporate Secretary. His experience at Allergan included serving as lead attorney for all business development transactions, including the $70 billion sale of Allergan to Actavis. He also served as a member of the Allergan Medical Management Team. During his early career, Maletta was an Associate Attorney at Skadden, Arps, Slate, Meagher and Flom LLP. Maletta earned both his bachelor's degree in political science and his law degree from the University of Minnesota.